Improving Delirium Screening and Detection in the Emergency Department (ED): The Implementation and Evaluation of the ED Delirium Detection Program
Abstract
Background: Delirium is missed in over 75% of older adults presenting to the Emergency Department (ED). The study aimed to determine the efficacy of the ED Delirium Detection Program (ED-DDP) to improve delirium detection while evaluating implementation outcomes.
Methods: The ED-DDP consisted of a train-the-trainer model where delirium champions (DCs) trained ED nurses to perform delirium screening using an electronic health record (EHR)-embedded Brief Confusion Assessment Method (bCAM). The ED-DDP was implemented across 3 diverse EDs using a stepped-wedge cluster randomized trial, consisting of control, implementation, and intervention periods. The RE-AIM (Reach, Efficacy, Adoption, Implementation, Maintenance) framework guided outcome assessments. Efficacy was defined as delirium detection between control and intervention periods. Implementation outcomes were assessed via quantitative (surveys, training logs, EHR) and qualitative (semi-structured interviews) methods.
Results: Across the 3 ED sites, 94.4% (n = 17/18) of DCs completed delirium training and 94.4% scored ≥ 80% on the post-workshop assessment (Implementation/Fidelity). Over 90% (91.1%, n = 195/214) of nurses agreed to receive training by DCs (Adoption); the average score during nurse bCAM spot checks was 73.3% (Implementation-Fidelity). After ED-DDP implementation, the odds of delirium screening were 11.5 times higher (95% CI: [6.0, 22.3], p < 0.001), when adjusting for time and site clustering (Penetration);…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 195 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.